Bradykinin receptor antagonists function by binding to the B1 or B2 receptors, thereby preventing bradykinin from exerting its biological effects. The inhibition of these receptors mitigates the downstream signaling pathways that lead to inflammation, vasodilation, and pain. This mechanism is crucial in conditions where bradykinin is excessively produced or its action is dysregulated.
